Evidence map›Paper›PMID 39251552›Full record

ArticleTransgenic research2024

NORE1A loss promotes MASLD/MASH.

Howard Donninger, Katherine Hobbing, Gavin E Arteel, Geoffrey J Clark

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transgenic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Howard DonningerDepartment of Medicine, University of Louisville, Louisville, KY, USA.
Katherine HobbingDeptartment of Pharmacology, University of Cincinnati, Cincinnati, USA.
Gavin E ArteelDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, USA.
Geoffrey J ClarkDepartment of Pharmacology & Toxicology, University of Louisville, Geoffrey J Clark, 417, CTRB, 505 S. Hancock St., Louisville, KY, 40202, USA. Gjclar01@louisville.edu.

Funding

Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVID A GELLER · 2019 to 2026
$10.9M
Novel Biomarkers for Post-Liver Transplant NASH FibrosisR01DK130294 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E, BENOS, PANAGIOTIS V · 2022 to 2025
$2.8M
CCR NIH HHS R01 CA133171-01A2NIDDK NIH HHS P30 DK120531NIDDK NIH HHS R01 DK130294
6 · The paper itself

Abstract

NORE1A (RASSF5) is a tumor suppressor that is frequently down-regulated in liver tumors. It is an upstream component of the HIPPO pathway, a key regulator of liver development and metabolism. HIPPO disruption can lead to the development of MASLD/MASH. While studying the phenotype of NORE1A knockout mice, we noticed that they exhibit no overt liver tumor phenotype, but have a strong propensity to develop fatty livers characteristic of MASLD/MASH. Additionally, knockdown of NORE1A in liver cells upregulates sterol regulator element binding protein 1 (SREBP1), whose deregulation is central to the development MASLD. Examination of primary human MASLD samples showed an inverse correlation between the expression of NORE1A protein and TAZ, a downstream effector of the HIPPO pathway. Thus, loss of NORE1A expression may contribute to the development of MASLD/MASH in humans and NORE1A knockout mice may provide a new MASLD/MASH model that more accurately mimics the human disease.

Indexed as

Mice, KnockoutAdaptor Proteins, Signal TransducingAnimalsApoptosis Regulatory ProteinsDisease Models, AnimalFatty LiverGTPase-Activating ProteinsHippo Signaling PathwayHumansLiverLiver NeoplasmsMiceProtein Serine-Threonine KinasesSignal TransductionSterol Regulatory Element Binding Protein 1Trans-ActivatorsAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsGTPase-Activating ProteinsProtein Serine-Threonine KinasesSterol Regulatory Element Binding Protein 1Trans-ActivatorsTranscription FactorsWwtr1 protein, mouseMASHMASLDNORE1ARASSF5

Identifiers

PMID39251552
PMCPMC12057061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.